The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | The CANDOR trial extended follow-up: daratumumab for R/R myeloma
Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, presents updated efficacy data from the Phase III randomized CANDOR study (NCT03158688) evaluating carfilzomib (K) and dexamethasone (d), with or without additional daratumumab (D), in patients with relapsed/refractory (R/R) multiple myeloma. Previous data analysis showed that KdD gave superior survival results to Kd. After an additional 11-month follow-up, giving a median follow-up of 27.8 months and 27.0 months for the KdD and Kd arms, respectively, the progression-free survival benefit was maintained, with a significant prolongation of 13.4 months in the KdD arm. No new safety signals were identified, resulting in a favorable benefit-risk profile. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Advisory boards: Amgen, Bristol Myers Squibb, Takeda, BeiGene, Janssen
